5.2
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
View/Download PDF

Translate this page into:

Original Article
8 (
1
); 78-92
doi:
10.1016/j.arabjc.2011.01.009

Oxovanadium(IV) complexes of medicinal relevance: Synthesis, characterization, and 3D-molecular modeling and analysis of some oxovanadium(IV) complexes in O,N-donor coordination matrix of sulfa drug Schiff bases derived from a 2-pyrazolin-5-one derivative

Coordination and Bioinorganic Chemistry Laboratory, Department of P.G. Studies and Research in Chemistry, R.D. University, Jabalpur 482 001, India

*Corresponding author. Tel.: +91 761 2601303; fax: +91 761 2603752 rcmaurya1@gmail.com (R.C. Maurya)

Disclaimer:
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.

Peer review under responsibility of King Saud University.

Available online 18 January 2011

Abstract

The present paper reports the synthesis and characterization of some new oxovanadium(IV) complexes of composition[VO(L)2(H2O)]·H2O, where LH = N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfadiazine (bumphp-sdzH), N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfaguanidine (bumphp-sgnH), N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfani-lamide (bumphp-snmH), and N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfamerazine (bumphp-smrH). These complexes were prepared by the reaction of vanadyl sulfate pentahydrate with the ligands in 1:2 metal–ligand ratios, in ethanol. The compounds so obtained were characterized by different physicochemical studies, such as, elemental analyses, molar conductance, and magnetic measurements, thermogravimetry, cyclic voltammetry, infrared, electron spin resonance, and electronic spectral studies. The overall IR studies conclude that the ligands in the present investigation behave as monobasic bidentate O,N-donors. The 3D molecular modeling and analysis for bond lengths and bond angles have also been carried out for one of the representative compounds,[VO(bumphp-sdz)2(H2O)]·H2O (1) to substantiate the proposed structure. Based on these studies suitable octahedral structures have been proposed for these complexes.

Keywords

Oxovanadium(IV) complexes
O,N-Donor sulfa drug based organic matrix
Bioinorganic
Medicinal relevance
3D Molecular modeling
1

1 Introduction

Acylpyrazolones, originally investigated by Jensen (1959a,b), have been employed for several applications (Marchetti et al., 2000a,b), viz., as pigments for dyes, as metal extractants from acidic solutions and also as sequestering agents toward polluting metal ions, such as cadmium and lead. These ligands have played and continue to play an important role in the development of coordination compounds that have found wide application in several fields, from new materials to catalysts, as precursors for CVD in the microelectronic industry and as potential antitumourals (Marchetti et al., 2005).

The pyrazolone derivatives have been reported to possess strong antibacterial, antihistaminic and antifungal, analgesic, antipyretic, anti-inflammatory, and anti-rheumatic activities (Merck Index, 1983). They also show antidiabetic (Goodman and Gilman, 1970), anticancer (Garg and Singh, 1970), and antineoplastic (Wilson and Bottigleri, 1962) properties.

The derivatives of Sulfonamide exhibit a range of bioactivities, including anti-angiogenic (Funahashi et al., 2002; Semba et al., 2004), anti-tumor (Semba et al., 2004; Sławínski et al., 2005), anti-inflammatory and anti-analgesic (Chen et al., 2005), anti-tubercular (Gadad et al., 2004), anti-glaucoma (Agrawal et al., 2004), anti-HIV (Yeung et al., 2005), cytotoxic (Encío et al., 2005), anti-microbial (Nieta et al., 2005), and anti-malarial (Domínguez, et al., 2005) agents. The sulfonamide derivatives are also known to exhibit a wide variety of pharmacological activities (Yoshino et al., 1992; Toth et al., 1997; Medina et al., 1999) through exchanges of different functional groups without the modification of the structural –S(O)2N(H)– feature. The synthesis of metal sulfonamide compounds had received much attention due to the fact that sulfanilamides were the first effective chemotherapeutic agents to be employed for the prevention and cure of bacterial infections in humans (Mohamed and Gad-Elkareem, 2007). The pharmacological activity of these types of molecules is often enhanced by complexation with metal ions (Bult and Sigel, 1983; Casanova et al., 1983). Moreover, some metal complexes of these ligands have been found to promote rapid healing of burns in human and animals (De Oliveira et al., 2008; Baenziger et al., 1983).

Vanadium plays an important role in life and one of its most relevant properties identified thus for is its capacity to act as an insulin-enhancing agent, either in the form of its inorganic salts or complexes with organic ligands (Rangel et al., 2006). It has been observed that simple inorganic vanadium compounds are more toxic than vanadium compounds with organic ligands and the efficacy of metal based therapeutic agents’ changes drastically by making changes in the organic ligands that are attached to the metal center (Mahroof-Tahir et al., 2005). For any complex considered for therapeutic use, it is important to consider the intrinsic toxicity of the ligand, especially if the treatment is predicted for long periods (Pressoa et al., 2003). Great efforts have, therefore, been made to synthesize oxovanadium(IV) complexes of high biological activity and low toxicity which are readily absorbed. Many oxovanadium(IV) complexes with various coordination modes (Thompson and Orvig, 2001; Sakurai et al., 2002; Thompson et al., 1999; Maurya and Rajput, 2006; Ghosh et al., 2005) have been prepared, viz., VO(O4), VO(S2N2), VO(S4), VO(N3O), and VO(N2O2), and the relationship between their structures and insulin-mimetic activities has been examined by evaluating both in vivo and in vitro results. The bis(ethylmaltolato)oxovanadium(IV) (BEOV) has completed phase I clinical trial in humans in the treatment of type-1 and type-2 diabetes mellitus (Thompson and Orvig, 2006).

Besides the antidiabetic action, vanadium complexes are known to possess potent anticancer activity (Kieler et al., 1965; Dessoize, 2004), which deserves increasing attention for the application to biomedical sciences (Etcheverry et al., 2008). Recent studies indicate the chemopreventive efficacy of vanadium in the inhibition of chemically induced carcinomas of the liver, colon, and mammary gland and has substantially documented the role of vanadium in the prevention of DNA–protein crosslinks, DNA chain break, chromosomal aberrations (Molinuevo et al., 2008; Chakraborty et al., 2006; Chattopadhyay et al., 2005; Kanna et al., 2004, 2005; Ray et al., 2004, 2005), reduction of tumor incidence and average number of tumors (33, Bishayee et al., 2000; Kanna et al., 2003), suppression of tumor marker genes like GST, GST-P, GGT, and MT (Ray et al., 2004). On the other hand, when using in vitro models it has been shown that some vanadium complexes displayed antitumoural actions (Barrio et al., 2003; D’Cruz and Uckun, 2002; Ding et al., 1999; Etcheverry et al., 2002; Evangelou et al., 2002; Molinuevo et al., 2004). Knowledge gained from in vitro studies has advanced vanadium research into the preclinical in vivo phase (Bishayee et al., 2010).

It has also been recognized that vanadium as a micronutrient prevents the minor wear and tear of the essential critical molecules of the cell like DNA, proteins, etc. in humans (Fenech and Ferguson, 2001) Thus, it has a role in DNA maintenance reactions and may protect the genomic instability that may be leading to cancer (Ray et al., 2006).

Recent studies (D’Cruz et al., 2003; Shigeta et al., 2003) showed that oxovanadium complexes of thiourea and vanadium substituted polyoxotungstates exhibit potent anti-HIV properties toward infected immortalized T-cells. However, the instability of vanadium(IV) complexes under physiological conditions has been frequently encountered (Raymond et al., 2007). Some oxovanadium(IV) complexes of porphyrin derivatives {[VO(N4)] type} were evaluated for their inhibitory effects on HIV-1(BaL) (Human Immunodeficiency Virus) replication in Hut/CCR5 cells (Raymond et al., 2007).

Earlier reports from our laboratory described the synthesis and characterization of metal chelates of ruthenium(II) (Maurya et al., 1994), dioxomolybdenum(VI) (Maurya et al., 2004, in press), oxovanadium(IV) (Maurya and Rajput, 2006), Cu(II), Ni(II), Co(II), Zn(II), Sm(III), Th(IV), and U(VI)O2 (Maurya et al., 2007) chelates with some Schiff base ligands derived from sulfa drugs.

Considering the pronounced biological activity of acylpyrazolones, and of sulfa drug derivatives, in view of the importance of vanadium compounds mentioned above, and also extending our search for more efficacious vanadium compounds, a study was undertaken of the coordination chemistry of oxovanadium(IV) complexes {[VO(N2O2)] type} involving pyrazolone based sulfa drug Schiff bases, viz., N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfadiazine (bumphp-sdzH, I), N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfaguanidine (bumphp-sgnH, II), N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfanilamide (bumphp-snmH, III), and N-(4′-butyrylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)sulfamerazine (bumphp-smrH, IV) (Fig. 1). The present communication describes the results of such a study.

Keto-enol tautomerism and intramolecular hydrogen bonding in Schiff bases.
Figure 1
Keto-enol tautomerism and intramolecular hydrogen bonding in Schiff bases.

2

2 Experimental

2.1

2.1 Materials

Vanadyl sulfate pentahydrate, calcium hydroxide, butyryl chloride, dimethyl formamide, sulfa drugs, viz., sulfamerazine (Thomas Baker Co. Ltd., Mumbai, India), sulfadiazine, sulphaguanidine and sulfanilamide (Sigma Chemicals Co., USA), and 3-methyl-1-phenyl-2-pyrazolin-5-one (Lancaster Research Chemicals, England) were used as supplied. All other chemicals used were of analytical grade.

2.2

2.2 Preparation of 3-methyl-1-phenyl-4-butyryl-2-pyrazolin-5-one (bumphpH)

It was prepared by the method reported elsewhere (Jensen, 1959a,b) with modification. Into a 1-L 3-necked quick fit flask containing DMF (100 mL) and carrying a dropping funnel, a mechanical stirrer, and a reflux condenser was placed 3-methyl-1-phenyl-2-pyrazolin-5-one (17 g, 0.098 mol). A solution was obtained by gentle heating and stirring. Calcium hydroxide (10 g, 0.14 mol) was added and butyryl chloride (10.33 mL) was added drop wise within 2–3 min. The reaction was exothermic and the reaction mixture became a paste. The mixture was allowed to cool and then refluxed with stirring for 1 h on a sand bath, during which period, the bright yellow complex, formed initially, turned yellowish brown. The complex was decomposed by pouring the reaction mixture into chilled dilute hydrochloric acid solution (500 mL, 2 N). A yellowish brown solid settled, which was filtered on a sintered glass crucible, washed with distilled water until the washings were colorless and dried in air and recrystallized from n-heptane. Melting point, 65 °C, yield, 70%.

2.3

2.3 Synthesis of Schiff bases

The Schiff bases with sulfa drugs were prepared as follows: An ethanolic solution (15 mL) of bumphpH (0.488 g, 2 mmol) was added to the solution of sulfadiazine (0.500 g, 2 mmol), sulfanilamide (0.344 g, 2 mmol), sulfaguanidine (0.428 g, 2 mmol), or sulfamerazine (0.528 g, 2 mmol) in ethanol. The resulting solution was refluxed with stirring for 4–5 h and then filtered to remove the insoluble sulfa drug, if any. The filtrate so obtained was concentrated on a water bath and left overnight at room temperature when colored crystals of Schiff bases separated out from their respective solutions. The crystals thus obtained were washed with ethanol and dried in vacuo. The characterization data of Schiff bases are given in Tables 1 and 2.

Table 1 Characterization data of the synthesized sulfa drug Schiff base ligands.
S. No. Schiff bases (empirical formula) (F.W.) Found/(calcd.)% Color Decomp. temp. (°C)
C H N
I bumphp-sdzH (C24H24N6SO3) (476) 60.12 (60.50) 5.38 (5.04) 17.30 (17.65) Light golden yellow 200
II bumphp-sgnH (C21H24N6SO3) (440) 57.59 (57.27) 5.78 (5.45) 19.41 (19.09) Yellow 150
III bumphp-snmH (C20H22N4SO3) (398) 60.13 (60.30) 5.38 (5.53) 14.39 (14.07) Daffodil 181
IV bumphp-smrH (C25H26N6SO3) (490) 61.56 (61.22) 5.16 (5.31) 17.43 (17.14) Yellow 190
Table 2 IR spectral data of the synthesized ligands.
S. No. Ligands ν(C⚌N) (azomethine) ν(C–O) (enolic) ν(C⚌N2) (cyclic) ν(NH)/(NH2) ν(OH) νas(O⚌S⚌O)
I bumphp-sdzH 1630 1159 1591 3363 3435 1410
II bumphp-sgnH 1627 1138 1595 3338 3440 1388
3216
III bumphp-snmH 1627 1179 1581 3262 3328 1388
IV bumphp-smrH 1628 1153 1596 3389 3486 1403

2.4

2.4 Synthesis of complexes

The following general procedure was used in the synthesis of all the complexes. The salt VOSO4·5H2O (0.253 g, 1 mmol) was dissolved in 5 mL of water and this solution was added to a warmed, stirred ethanolic solution (∼15 mL) of the corresponding Schiff bases, bumphp-sdzH (0.952 g, 2 mmol), bumphp-sgnH (0.880 g, 2 mmol), bumphp-snmH (0.796 g, 2 mmol) or bumphp-smrH (0.980 g, 2 mmol). The resulting solution was refluxed for 10–12 h and then concentrated to half of its volume. The resulting colored precipitate was filtered and washed several times with ethanol to remove the unreacted ligand and the metal salt. The product was dried in vacuo. The analytical data are given in Table 3.

Table 3 Analytical data and some physical properties of the synthesized complexes.
S. No. Complexes (empirical formula, F.W.) Found/(calcd.)% Color Decomp. temp. (°C) Yield (%) Λm (Ohm−1 cm2 mol−1) μeff (B. M.)
C H N V
(1) [VO(bumphp-sdz)2(H2O)]·H2O (C48H52N12O10S2V) (1070.94) 54.52 4.64 15.76 4.49 Peppermint 225 65 12.5 1.74
(54.74) (4.75) (15.96) (4.84)
(2) [VO(bumphp-sgn)2(H2O)]·H2O (C42H50N12O9S2V) (980.94) 51.69 5.32 17.27 5.37 Pastel green 210 40 16.3 1.75
(51.38) (5.10) (17.13) (5.19)
(3) [VO(bumphp-snm)2(H2O)]·H2O (C40H46N8O9S2V) (896.94) 53.29 5.37 12.24 5.79 Pistachio 200 50 14.2 1.78
(53.52) (5.13) (12.49 (5.68)
(4) [VO(bumphp-smr)2(H2O)]·H2O (C50H54N12O9S2V) (1080.94) 55.32 5.13 15.71 4.54 Pastel green 220 50 19.2 17.6
(55.51) (5.00) (15.54) (4.71)

2.5

2.5 Analyses

Carbon, hydrogen, and nitrogen were determined micro-analytically at SAIF, Indian Institute of Technology, Mumbai. The vanadium content of each of the complexes was determined as follows. One hundred milligrams of the sample of the compound were placed in a silica crucible, decomposed by gentle heating and then was added 1–2 mL of concentrated HNO3, 2–3 times. An orangish mass (V2O5) was obtained after decomposing and complete drying. It was dissolved in minimum amount of dilute H2SO4, and the solution so obtained was diluted with distilled water to 100 mL in a measuring flask. The vanadium content of each of the complexes was determined volumetrically using decinormal KMnO4 solution as an oxidizing agent in the presence of sulfurous acid. The amount of vanadium in the sample solution was calculated using the standard (Furman, 1962) relationship: 1 mL of 0.1 N KMnO4 = 5.094 mg vanadium.

2.6

2.6 Physical methods

The following physical methods were used in the present investigation. Thermogravimety of a complex was performed on a Perkin–Elmer Thermoanalyser at S.A.I.F., Indian Institute of Technology, Mumbai. The solid-state infrared spectra were obtained using KBr pellets with a Perkin–Elmer model 1620 FT-IR spectrophotometer at the Central Drug Research Institute, Lucknow. Electronic spectra were recorded on an ATI Unicam UV-1–100 UV/vis Spectrophotometer in our laboratory. Conductance measurements were made in DMF solution using a Toshniwal conductivity bridge and dip-type cell with a smooth platinum electrode of cell constant 1.02. Magnetic measurements were done by a vibrating sample magnetometer at the Regional Sophisticated Instrumentation Centre, Indian Institute of Technology, Chennai. The decomposition temperatures of the complexes were recorded by an electrically operated melting point apparatus (Kumar Industries, Mumbai) of heating capacity up to 360 °C. Cyclic voltammetric measurements were carried out on an ECDA-001 basic electrochemistry system. A three-electrode system consisting of (i) a platinum disk working electrode, (ii) a platinum wire counter electrode and (iii) a Ag/AgCl reference electrode was used. A 10 mL glass cell with a Teflon cell cover holding working, counter, and reference electrodes and deoxygenating purge tube formed the sample cell. Prior to each run, the working electrode was polished using polishing nylon cloth over a glass plate. The sample solution was deoxygenated by passing purified nitrogen gas through the solution. The X-Band and EPR spectra of the complexes were measured on a Bruker ESP X-band EPR spectrometer using powdered samples at the Regional Sophisticated Instrumentation Centre, Indian Institute of Technology, Chennai.

2.7

2.7 3D Molecular modeling studies

The 3D molecular modeling of one of the synthesized compounds was carried out on CS Chem 3D Ultra Molecular Modeling and Analysis Programme (www.cambridgesoft.com). It is an interactive graphics program that allows rapid structure building, geometry optimization, and molecular display. It has the ability to handle transition metal compounds.

3

3 Results and discussion

The oxovanadium(IV) complexes were prepared according to the following equations: VOSO 4 · 5 H 2 O + 2 LH Reflux H 2 O, C 2 H 5 OH [ VO ( L ) 2 ( H 2 O ) ] · H 2 O + H 2 SO 4 where LH = bumphp-sdzH (1), bumphp-sgnH (2), bumphp-snmH (3), bumphp-smrH (4).

The resulting complexes are soluble in DMF and DMSO, partially soluble in acetonitrile and insoluble in ethanol, methanol, and carbon tetrachloride. They are non-hygroscopic and colored solids. Their physical properties are given in Table 3.

3.1

3.1 Infrared spectral studies

The important spectral bands of the synthesized ligands as well as the complexes are presented in Tables 2 and 4, respectively. All of the Schiff base ligands in the present investigation exhibit a broad band centered at 3328–3486 cm−1. This suggests the involvement of the 5-OH group in intramolecular hydrogen (Maurya et al., 1997) bonding with the lone pair of azomethine nitrogen. It also suggests that the ligands exist in enol form in the solid state (Maurya et al., 2002a,b,c).

Table 4 Important IR spectral bands of the synthesized complexes.
S. No Complexes ν(C⚌N) (azometh.) ν(C–O) (enolic) ν(C⚌N2) (cyclic) ν(V⚌O) ν(V–O) ν(V–N) ν(OH) ν(NH)/(NH2)
(1) [VO(bumphp-sdz)2(H2O)]·H2O 1615 1164 1591 975 639 486 3475 (br) 3348
(2) [VO(bumphp-sgn)2(H2O)]·H2O 1612 1150 1595 980 634 491 3470 (br) 3317
3245
(3) [VO(bumphp-snm)2(H2O)]·H2O 1617 1195 1585 980 634 486 3313 (br) 3230
(4) [VO(bumphp-smr)2(H2O)]·H2O 1607 1180 Merged with ν(C⚌N) 990 625 502 3450 (br) 3338

The Schiff base ligands used in the present investigation contain six potential donor sites: (i) the enolic oxygen; (ii) the cyclic nitrogen, N1; (iii) the cyclic nitrogen, N2; (iv) the azomethine nitrogen; (v) the sulfonamide (–SO2NH) oxygen or nitrogen and; (vi) the ring nitrogen of sulfa drug. All the Schiff base ligands show a sharp and strong band due to ν(C⚌N) of the azomethine group at 1627–1630 cm−1. The observed low-energy shift of this band in the chelates and appearing at 1607–1617 cm−1, suggests the coordination of the azomethine nitrogen (Maurya et al., 2002a,b,c).

The ν(C⚌N2) (cyclic) band arising from the pyrazolone moiety of the ligands appears at 1581–1596 cm−1 and does not show any appreciable change in its respective positions in the complexes. This observation indicates the non-participation of the ring nitrogen N2 in coordination. The coordination of the ring nitrogen N1 is unfavorable due to the steric demand of the bulky phenyl ring attached to it.

The ν(NH) mode of the sulfonamide group/amino group in the uncoordinated Schiff bases remains almost unchanged in the spectra of their complexes (see Tables 2 and 4). This suggests that the sulfonamide nitrogen/amino group is not taking part in coordination. The band appearing at 1388–1410 cm−1 in the ligands is assigned to νas(O⚌S⚌O). This band remains almost at the same position in the complexes and hence suggests that the sulfonamide oxygen is not taking part in coordination with the metal center. The reaction of the enolic Schiff bases with VO2+ ion with the elimination of a proton is revealed by the presence of a new band in the complexes at 1150–1195 cm−1 as compared to that of the Schiff bases at 1138–1179 cm−1 due to ν(C–O) (enolic) (Maurya et al., 1996). The appearance of a broad band centered at 3313–3475 cm−1 and assignable as ν(OH) suggests the presence of lattice/coordinated water molecules in the complexes.

Most of the oxovanadium(IV) complexes exhibit a strong band near 1000 cm−1, which has been assigned to ν(V⚌O) (Selbin, 1966). In contrast, several oxovanadium(IV) complexes have been reported in which this stretching mode appears at quite lower (Maurya et al., 2001) wave numbers, around 900 cm−1. The shift of ν(V⚌O) band to lower wave numbers has been suggested due to the presence of a slight ⋯V⚌O⋯V⚌O⋯ type interaction occurring between a vanadyl oxygen of one molecule with a vanadium metal in another molecule (Boas and Pessoa, 1987). In the present work, the ν(V⚌O) mode is found at 975–990 cm−1 thereby suggesting the absence of ⋯V⚌O⋯V⚌O⋯ type interaction in these complexes. The IR spectra of the Schiff base ligand (bumphp-snmH, III) and its complex,[VO(bumphp-snm)2(H2O)]·H2O (3) are given in Figs. 2 and 3, respectively.

IR spectrum of bumphp-snmH (III).
Figure 2
IR spectrum of bumphp-snmH (III).
IR spectrum of[VO(bumphp-snm)2(H2O)]·H2O (3).
Figure 3
IR spectrum of[VO(bumphp-snm)2(H2O)]·H2O (3).

3.2

3.2 Electronic spectral studies

The electronic spectra of these compounds were recorded in 10−3 M dimethylformamide solutions in the range of 280–800 nm. The λmax of the electronic spectral peaks and the respective molar extinction coefficients along with the tentative assignments are given in Table 5. Besides high intensity charge transfer transitions, all these complexes displayed one low intensity d–d transition which may be assigned to b 2 1 a 1 * transition (Lever, 1984). The assignment of b 2 1 a 1 * transition in each case assumes idealized C2v symmetry. These spectra are typical of oxovanadium(IV) complexes (Maurya and Rajput, 2004; Dutta et al., 1997). The electronic spectrum of the compound,[VO(bumphp-sgn)2(H2O)]·H2O (2) is shown in Fig. 4.

Table 5 Electronic spectral data of the synthesized complexes.
S. No. Complex λmax (nm.) ε (L mol−1 cm−1) Peak assignment
(1) [VO(bumphp-sdz)2(H2O)]·H2O 320 2492 Charge transfer transition b 2 a 1 *
438.5 341
(2) [VO(bumphp-sgn)2(H2O)]·H2O 328 2894 Charge transfer transition b 2 a 1 *
440 270
(3) [VO(bumphp-snm)2(H2O)]·H2O 333 3178 Charge transfer transition b 2 a 1 *
433 294
(4) [VO(bumphp-smr)2(H2O)]·H2O 332 3238 Charge transfer transition b 2 a 1 *
427 267
Electronic spectrum of[VO(bumphp-sgn)2(H2O)]·H2O (2).
Figure 4
Electronic spectrum of[VO(bumphp-sgn)2(H2O)]·H2O (2).

3.3

3.3 ESR spectral studies

The X-band EPR spectra of compounds, (2) and (4) were recorded using the microwave frequencies 9.09 GHz and 9.10 GHz, respectively in frozen DMF solution without DPPH at LNT. Each spectrum shows an eight-line pattern, a characteristic of an unpaired electron being coupled with a vanadium nuclear spin (I = 7/2). This means that the unpaired electron is in the vicinity of I = 7/2 of its own mother nucleus. Thus, the isotropic ESR spectrum of a magnetically dilute oxovanadium(IV) complex gives (2 × 7/2 + 1 = 8 lines). The calculated ESR parameters from the spectra of both the complexes are given in Table 6.

Table 6 ESR spectral parameters of the complexes.
Compound A A|| Aav g g|| gav
[VO(bumphp-sgn)2(H2O)]·H2O 180 240 200 1.898 1.896 1.897
[VO(bumphp-smr)2(H2O)]·H2O 180 140 166.67 1.90 1.976 1.925

The observed gav values for both the complexes deviate from the free ion value 2.0036, which suggest that the resulting complexes are covalent in nature (Dutta and Syamal, 1993). Moreover, the features of the spectra of these complexes are indicative of monomeric oxovanadium(IV) complexes (Maurya et al., 2002a,b,c). The ESR spectrum of compounds,[VO(bumphp-sgn)2(H2O)]·H2O (2) and[VO(bumphp-smr)2(H2O)]·H2O (4) is given in Fig. 5a and b, respectively.

ESR spectrum of[VO(bumphp-sgn)2(H2O)]·H2O (2).
Figure 5a
ESR spectrum of[VO(bumphp-sgn)2(H2O)]·H2O (2).
ESR spectrum of[VO(bumphp-smr)2(H2O)]·H2O (4).
Figure 5b
ESR spectrum of[VO(bumphp-smr)2(H2O)]·H2O (4).

3.4

3.4 Thermogravimetric studies

The thermogram of one of the representative compounds,[VO(bumphp-snm)2(H2O)]·H2O (3) were recorded in the temperature range from 30 to 1000 °C at a heating rate of 15 °C/min. This compound shows a weight loss of 4% in the temperature range 80–140 °C (calcd. wt. loss for 2 mol of H2O, 4%). As this weight loss starts from 80 °C and completes around 140 °C, this shows the presence (Maurya et al., 2003; Zhao et al., 2008) of one lattice water and one coordinated water molecule in the complex. After this weight loss, the compound remains stable up to 300 °C and thereafter, shows a steep weight loss. The ultimate weight loss of 84% at ∼950 °C roughly corresponds to the removal of all the ligand moieties from the complex (calcd. wt. loss for removal of all the ligand moieties, 92.7%). The final residue attaining a constant weight (observed, 16%) over 950 °C roughly corresponds to V2O5 (calculated, 20.27%). This weight loss data, thus, agree well with the IR results for this complex. The thermogram of compound,[VO(bumphp-snm)2(H2O)]·H2O (3) is given in Fig. 6.

Thermogram of[VO(bumphp-snm)2(H2O)]·H2O (3).
Figure 6
Thermogram of[VO(bumphp-snm)2(H2O)]·H2O (3).

3.5

3.5 Magnetic measurements

The magnetically dilute oxovanadium(IV) complexes usually exhibit magnetic moments in line with spin-only value of 1.73 B.M. At room temperature, the observed value of the magnetic moments for the present complexes, are in the range 1.74–1.76 B.M. These data suggest that the complexes under this investigation are mononuclear (Dutta et al., 1997).

3.6

3.6 Conductance measurements

The observed molar conductances (12.5–19.7 ohm−1 cm2 mol−1) in 10−3 M DMF solutions of these Schiff base complexes are given in Table 3, and are consistent with the non-electrolytic nature of the complexes. Such a non-zero molar conductance value for each of the complexes in the present study is most probably due to the strong donor capacity of DMF, which may lead to the displacement of anionic ligand and change of electrolyte (Geary, 1971) type.

3.7

3.7 Cyclic voltammetric studies

Cyclic voltammetric measurements of two representative complexes,[VO(bumphp-sdz)2(H2O)]·H2O (1) and[VO(bumphp-snm)2(H2O)]·H2O (3), were carried out on an ECDA-001 basic electrochemistry system in order to assess the suitability of ligand environments in the present complexes to facilitate electron transfer reactions. The complexes were dissolved in dimthyformamide and the cyclic voltammograms were recorded in the scan range of 2000 to −2000 mV. The reduction of these complexes to +III oxidation state (usually expected in such complexes) were achieved by waves with Er values (Maurya and Rajput, 2004; Dai et al., 1996) in the range from −788.45 to −913.45 mV against the saturated Ag/AgCl electrode (Table 7). Other important parameters are also included in this table. The deviations of ipc/ipa from 1 in the present cases suggest that the redox couple is not reversible. This may be due to a slow electron transfer reaction. This is again reflected by the unusually high values of ΔE in the range of 346.3–403.9 mV, not following the reversibility criterion (Kissinger and Heineman, 1984), Δ E p = E pa - E pc = 0.059 n The cyclic voltammogram of compound (3) is shown in Fig. 7.

Table 7 Some important parameters of cyclic voltammogram of the complexes.
Compd. Epc Epa E r = E pc + E pa 2 E(Epc − Epa) ipc ipa ipc/ipa
(1) −711.5 −1115.4 −913.45 403.9 155.5 133.4 1.17
(3) −615.3 −961.6 −788.45 346.3 160 220 0.73

Supporting electrolyte: tetrabutylammonium tetrafluoroborate,[CH3(CH2)3]4NBF4 (50 mmol); concentration of complexes; 1 mmol; all the potentials are referenced to Ag/AgCl electrode; Er = 0.5(Epa + Epc), where Epa and Epc are anodic and cathodic potentials.

Cyclic voltammogram of[VO(bumphp-snm)2(H2O)]·H2O (3).
Figure 7
Cyclic voltammogram of[VO(bumphp-snm)2(H2O)]·H2O (3).

3.8

3.8 3D-Molecular modeling and analysis

In view of the hexa-coordination of all the complexes (vide infra), and also taking into account the well established square pyramidal structure (Sakurai et al., 1995) of bis(picolinato)oxovanadium(IV)[having two monoprotic bidentate (O,N-donor) picolinate ligand, similar to two monoprotic O,N-donor sulfa drug based Schiff base ligands (LH) used in the present investigation, and occupying equatorial positions cis to each other, and oxo group at one of the axial positions], the molecular modeling of a representative compound,[VO(bumphp-sdz)2(H2O)]·H2O (1) is based on its octahedral structure with an axial oxo group and water molecule trans to O (oxo) and two O,N-donor LH ligands at the equatorial positions cis to each other. The details of bond lengths and bond angles as per the 3D structure (Fig. 8) are given in Tables 8 and 9, respectively. For convenience of looking over the different bond lengths and bond angles, the various atoms in the compound in question are numbered in Arabic numerals. In all, 382 measurements of the bond lengths (140 in number), plus the bond angles (242 in number) are listed in the Tables 8 and 9. Except few cases, optimal values of both the bond lengths and the bond angles are given in the Tables along with the calculated ones. The actual (calculated) bond lengths/bond angles given in Tables are obtained as a result of energy optimization in CHEM 3D Ultra, while the optimal bond length/optimal bond angle values are the most desirable/favorable (standard) bond lengths/bond angles established by the builder unit of the CHEM 3D. The missing of some values of standard bond lengths/bond angles may be due to the limitations of the software, which we had already noticed in modeling of other systems (Maurya et al., 2007, 2008, in press). In most of the cases, the actual bond lengths and bond angles are close to the optimal values, and thus the proposed structure of the compound (1) as well as of the others are acceptable (Maurya and Rajput, 2007; Maurya et al., 2007, 2008, in press).

3D structure of[VO(bumphp-sdz)2(H2O)]·H2O (1).
Figure 8
3D structure of[VO(bumphp-sdz)2(H2O)]·H2O (1).
Table 8 Various bond lengths of compound[VO(bumphp-sdz)2(H2O)]·H2O (1).
S. No. Atoms Actual bond length Optimal bond length S. No. Atoms Actual bond length Optimal bond length
1 C(76)–H(134) 1.113 1.113 71 C(36)–C(37) 1.337 1.42
2 C(76)–H(133) 1.113 1.113 72 C(35)–H(109) 1.1 1.1
3 C(76)–H(132) 1.113 1.113 73 C(35)–C(36) 1.337 1.42
4 C(76)–H(131) 1.113 1.113 74 C(34)–H(108) 1.1 1.1
5 C(2)–H(84) 1.113 1.113 75 C(34)–C(35) 1.337 1.42
6 C(2)–H(83) 1.113 1.113 76 C(33)–H(107) 1.1 1.1
7 C(2)–H(82) 1.113 1.113 77 C(33)–C(34) 1.337 1.42
8 C(2)–H(81) 1.113 1.113 78 C(32)–C(37) 1.337 1.42
9 C(1)–H(80) 1.113 1.113 79 C(32)–C(33) 1.337 1.42
10 C(1)–H(79) 1.113 1.113 80 C(31)–H(106) 1.113 1.113
11 C(1)–H(78) 1.113 1.113 81 C(31)–H(105) 1.113 1.113
12 C(1)–H(77) 1.113 1.113 82 C(30)–H(104) 1.113 1.113
13 N(75)–H(130) 1.05 1.05 83 C(30)–H(103) 1.113 1.113
14 C(74)–H(129) 1.1 1.1 84 C(30)–C(31) 1.523 1.523
15 C(73)–H(128) 1.1 1.1 85 C(29)–H(102) 1.113 1.113
16 C(73)–C(74) 0.9398 1.42 86 C(29)–H(101) 1.113 1.113
17 C(72)–H(127) 1.1 1.1 87 C(29)–H(100) 1.113 1.113
18 C(72)–C(73) 1.337 1.42 88 C(29)–C(30) 1.523 1.523
19 N(71)–C(72) 1.26 1.358 89 N(39)–C(28) 1.266 1.266
20 C(70)–N(75) 1.266 1.462 90 C(28)–C(31) 1.497 1.497
21 C(70)–N(71) 1.26 1.358 91 C(26)–O(27) 1.355 1.355
22 C(74)–N(69) 1.26 1.358 92 C(25)–C(28) 1.337 1.503
23 N(69)–C(70) 1.26 1.358 93 C(25)–C(26) 1.337 1.337
24 N(75)–S(66) 1.696 94 C(24)–C(38) 1.497 1.497
25 S(66)–O(68) 1.45 1.45 95 C(24)–C(25) 1.337 1.503
26 S(66)–O(67) 1.45 1.45 96 N(23)–C(24) 1.5526 1.26
27 C(65)–H(126) 1.1 1.1 97 N(22)–C(32) 1.266 1.462
28 C(64)–S(66) 1.79 98 N(22)–C(26) 1.266 1.462
29 C(64)–C(65) 1.337 1.42 99 N(22)–N(23) 1.23 1.426
30 C(63)–H(125) 1.1 1.1 100 N(39)–V(21) 2.075
31 C(63)–C(64) 1.337 1.42 101 V(21)–O(50) 1.86
32 C(62)–H(124) 1.1 1.1 102 V(21)–O(49) 1.5996
33 C(62)–C(63) 1.337 1.42 103 O(27)–V(21) 1.86
34 C(61)–C(62) 1.337 1.42 104 C(20)–H(99) 1.113 1.113
35 C(60)–H(123) 1.1 1.1 105 C(20)–H(98) 1.113 1.113
36 C(65)–C(60) 1.337 1.42 106 C(20)–H(97) 1.113 1.113
37 C(60)–C(61) 1.337 1.42 107 C(19)–H(96) 1.1 1.1
38 N(59)–H(122) 1.05 1.05 108 C(18)–H(95) 1.1 1.1
39 C(58)–H(121) 1.1 1.1 109 C(18)–C(19) 1.337 1.42
40 C(57)–H(120) 1.1 1.1 110 C(17)–H(94) 1.1 1.1
41 C(57)–C(58) 0.9398 1.42 111 C(17)–C(18) 1.337 1.42
42 C(56)–H(119) 1.1 1.1 112 C(16)–H(93) 1.1 1.1
43 C(56)–C(57) 1.337 1.42 113 C(16)–C(17) 1.337 1.42
44 N(55)–C(56) 1.26 1.358 114 C(15)–H(92) 1.1 1.1
45 C(54)–N(59) 1.266 1.462 115 C(15)–C(16) 1.337 1.42
46 C(54)–N(55) 1.26 1.358 116 C(14)–C(19) 1.337 1.42
47 C(58)–N(53) 1.26 1.358 117 C(14)–C(15) 1.337 1.42
48 N(53)–C(54) 1.26 1.358 118 C(13)–H(91) 1.113 1.113
49 O(50)–H(52) 0.986 119 C(13)–H(90) 1.113 1.113
50 O(50)–H(51) 0.986 120 C(12)–H(89) 1.113 1.113
51 N(59)–S(46) 1.696 121 C(12)–H(88) 1.113 1.113
52 S(46)–O(48) 1.45 1.45 122 C(12)–C(13) 1.523 1.523
53 S(46)–O(47) 1.45 1.45 123 C(11)–H(87) 1.113 1.113
54 C(45)–H(118) 1.1 1.1 124 C(11)–H(86) 1.113 1.113
55 C(44)–S(46) 1.79 125 C(11)–H(85) 1.113 1.113
56 C(44)–C(45) 1.337 1.42 126 C(11)–C(12) 1.523 1.523
57 C(43)–H(117) 1.1 1.1 127 V(21)–N(10) 1.8628
58 C(43)–C(44) 1.337 1.42 128 C(41)–N(10) 1.266 1.462
59 C(42)–H(116) 1.1 1.1 129 C(9)–C(13) 1.497 1.497
60 C(42)–C(43) 1.337 1.42 130 C(9)–N(10) 1.266 1.266
61 C(41)–C(42) 1.337 1.42 131 O(8)–V(21) 1.86
62 C(40)–H(115) 1.1 1.1 132 C(7)–O(8) 1.355 1.355
63 C(45)–C(40) 1.337 1.42 133 C(6)–C(9) 1.337 1.503
64 C(40)–C(41) 1.337 1.42 134 C(6)–C(7) 1.337 1.337
65 C(61)–N(39) 1.266 1.462 135 C(5)–C(20) 1.497 1.497
66 C(38)–H(114) 1.113 1.113 136 C(5)–C(6) 1.337 1.503
67 C(38)–H(113) 1.113 1.113 137 N(4)–C(5) 1.26 1.26
68 C(38)–H(112) 1.113 1.113 138 N(3)–C(14) 1.266 1.462
69 C(37)–H(111) 1.1 1.1 139 N(3)–C(7) 1.266 1.462
70 C(36)–H(110) 1.1 1.1 140 N(3)–N(4) 1.614 1.426
Table 9 Various bond angles of compound[VO(bumphp-sdz)2(H2O)]·H2O (1).
S. No. Atoms Actual bond angles Optimal bond angles S. No. Atoms Actual bond angles Optimal bond angles
1 H(134)–C(76)–H(133) 109.52 109.47 122 H(109)–C(35)–C(36) 119.9999 120
2 H(134)–C(76)–H(132) 109.4621 109.47 123 H(109)–C(35)–C(34) 120 120
3 H(134)–C(76)–H(131) 109.4618 109.47 124 C(36)–C(35)–C(34) 120.0001
4 H(133)–C(76)–H(132) 109.4417 109.47 125 H(108)–C(34)–C(35) 120.0004 120
5 H(133)–C(76)–H(131) 109.4417 109.47 126 H(108)–C(34)–C(33) 119.9996 120
6 H(132)–C(76)–H(131) 109.4999 109.47 127 C(35)–C(34)–C(33) 120
7 H(84)–C(2)–H(83) 109.52 109.47 128 H(111)–C(37)–C(36) 119.9993 120
8 H(84)–C(2)–H(82) 109.4619 109.47 129 H(111)–C(37)–C(32) 120.0003 120
9 H(84)–C(2)–H(81) 109.462 109.47 130 C(36)–C(37)–C(32) 120.0004
10 H(83)–C(2)–H(82) 109.4417 109.47 131 H(107)–C(33)–C(34) 119.9998 120
11 H(83)–C(2)–H(81) 109.4419 109.47 132 H(107)–C(33)–C(32) 120.0003 120
12 H(82)–C(2)–H(81) 109.4999 109.47 133 C(34)–C(33)–C(32) 119.9999
13 H(80)–C(1)–H(79) 109.5197 109.47 134 C(37)–C(32)–C(33) 119.9999 120
14 H(80)–C(1)–H(78) 109.4619 109.47 135 C(37)–C(32)–N(22) 120.0003 120
15 H(80)–C(1)–H(77) 109.4618 109.47 136 C(33)–C(32)–N(22) 119.9998 120
16 H(79)–C(1)–H(78) 109.4421 109.47 137 H(114)–C(38)–H(113) 109.5199 109
17 H(79)–C(1)–H(77) 109.4416 109.47 137 H(114)–C(38)–H(112) 109.462 109
18 H(78)–C(1)–H(77) 109.5001 109.47 139 H(114)–C(38)–C(24) 109.4619 110
19 H(129)–C(74)–C(73) 114.0213 120 140 H(113)–C(38)–H(112) 109.4419 109
20 H(129)–C(74)–N(69) 114.0215 116.5 141 H(113)–C(38)–C(24) 109.4419 110
21 C(73)–C(74)–N(69) 131.9572 123.5 142 H(112)–C(38)–C(24) 109.4998 110
22 H(128)–C(73)–C(74) 120.979 120 143 C(24)–N(23)–N(22) 108.8313 115
23 H(128)–C(73)–C(72) 120.978 120 144 C(62)–C(61)–C(60) 120.0004 120
24 C(74)–C(73)–C(72) 118.043 145 C(62)–C(61)–N(39) 120.0001 120
25 H(127)–C(72)–C(73) 120 120 146 C(60)–C(61)–N(39) 119.9995 120
26 H(127)–C(72)–N(71) 119.9999 116.5 147 H(106)–C(31)–H(105) 109.5206 109.4
27 C(73)–C(72)–N(71) 120.0001 123.5 148 H(106)–C(31)–C(30) 109.462 109.41
28 C(72)–N(71)–C(70) 115.0002 115 149 H(106)–C(31)–C(28) 109.4618 109.41
29 C(74)–N(69)–C(70) 114.9998 115 150 H(105)–C(31)–C(30) 109.4417 109.41
30 N(75)–C(70)–N(71) 120.0004 126 151 H(105)–C(31)–C(28) 109.4415 109.41
31 N(75)–C(70)–N(69) 119.9998 126 152 C(30)–C(31)–C(28) 109.4997 109.5
32 N(71)–C(70)–N(69) 119.9998 120 153 N(39)–C(28)–C(31) 120 125.3
33 H(130)–N(75)–C(70) 120.0004 118 154 N(39)–C(28)–C(25) 120.0001 120
34 H(130)–N(75)–S(66) 119.9996 155 C(31)–C(28)–C(25) 119.9999 121.4
35 C(70)–N(75)–S(66) 120 156 C(38)–C(24)–C(25) 130.9156 121.4
36 H(121)–C(58)–C(57) 114.0221 120 157 C(38)–C(24)–N(23) 130.9152 115.1
37 H(121)–C(58)–N(53) 114.0215 116.5 158 C(25)–C(24)–N(23) 98.1693 120
38 C(57)–C(58)–N(53) 131.9564 123.5 159 C(32)–N(22)–C(26) 124.5002 124
39 H(120)–C(57)–C(58) 120.9782 120 160 C(32)–N(22)–N(23) 124.4997 124
40 H(120)–C(57)–C(56) 120.9783 120 161 C(26)–N(22)–N(23) 111.0001 124
41 C(58)–C(57)–C(56) 118.0436 162 C(28)–C(25)–C(26) 119.9983 120
42 H(119)–C(56)–C(57) 119.9999 120 163 C(28)–C(25)–C(24) 128.9979 120
43 H(119)–C(56)–N(55) 120 116.5 164 C(26)–C(25)–C(24) 111.0003 120
44 C(57)–C(56)–N(55) 120.0001 123.5 165 O(27)–C(26)–C(25) 124.3002 124.3
45 C(56)–N(55)–C(54) 114.9999 115 166 O(27)–C(26)–N(22) 124.6986
46 C(58)–N(53)–C(54) 115.0001 115 167 C(25)–C(26)–N(22) 110.9991 120
47 N(59)–C(54)–N(55) 119.9999 126 168 H(95)–C(18)–C(19) 119.9998 120
48 N(59)–C(54)–N(53) 120.0001 126 169 H(95)–C(18)–C(17) 119.9999 120
49 N(55)–C(54)–N(53) 120 120 170 C(19)–C(18)–C(17) 120.0003
50 H(122)–N(59)–C(54) 119.9998 118 171 H(94)–C(17)–C(18) 120.0005 120
51 H(122)–N(59)–S(46) 120.0003 172 H(94)–C(17)–C(16) 120 120
52 C(54)–N(59)–S(46) 119.9999 173 C(18)–C(17)–C(16) 119.9995
53 H(102)–C(29)–H(101) 109.5203 109 174 H(93)–C(16)–C(17) 119.9998 120
54 H(102)–C(29)–H(100) 109.461 109 175 H(93)–C(16)–C(15) 119.9998 120
55 H(102)–C(29)–C(30) 109.462 110 176 C(17)–C(16)–C(15) 120.0004
56 H(101)–C(29)–H(100) 109.4418 109 177 H(96)–C(19)–C(18) 120.0001 120
57 H(101)–C(29)–C(30) 109.4421 110 178 H(96)–C(19)–C(14) 119.9999 120
58 H(100)–C(29)–C(30) 109.5 110 179 C(18)–C(19)–C(14) 120.0001
59 H(104)–C(30)–H(103) 109.52 109.4 180 H(92)–C(15)–C(16) 120.0007 120
60 H(104)–C(30)–C(31) 109.462 109.41 181 H(92)–C(15)–C(14) 119.9993 120
61 H(104)–C(30)–C(29) 109.462 109.41 182 C(16)–C(15)–C(14) 120
62 H(103)–C(30)–C(31) 109.4419 109.41 183 H(52)–O(50)–H(51) 119.9998
63 H(103)–C(30)–C(29) 109.4418 109.41 184 H(52)–O(50)–V(21) 120
64 C(31)–C(30)–C(29) 109.4996 109.5 185 H(51)–O(50)–V(21) 120.0003
65 H(87)–C(11)–H(86) 109.52 109 186 C(61)–N(39)–C(28) 121.5436 124
66 H(87)–C(11)–H(85) 109.4613 109 187 C(61)–N(39)–V(21) 121.544
67 H(87)–C(11)–C(12) 109.4615 110 188 C(28)–N(39)–V(21) 116.9124
68 H(86)–C(11)–H(85) 109.442 109 189 C(26)–O(27)–V(21) 109.4998
69 H(86)–C(11)–C(12) 109.4424 110 190 C(42)–C(41)–C(40) 119.9999 120
70 H(85)–C(11)–C(12) 109.5 110 191 C(42)–C(41)–N(10) 120 120
71 H(89)–C(12)–H(88) 109.5197 109.4 192 C(40)–C(41)–N(10) 120.0001 120
72 H(89)–C(12)–C(13) 109.4615 109.41 193 O(50)–V(21)–O(49) 128.1267
73 H(89)–C(12)–C(11) 109.4619 109.41 194 O(50)–V(21)–N(39) 134.7233
74 H(88)–C(12)–C(13) 109.4416 109.41 195 O(50)–V(21)–O(27) 102.8229
75 H(88)–C(12)–C(11) 109.4424 109.41 196 O(50)–V(21)–N(10) 121.5001
76 C(13)–C(12)–C(11) 109.5003 109.5 197 O(50)–V(21)–O(8) 129.5918
77 N(75)–S(66)–O(68) 109.4417 198 O(49)–V(21)–N(39) 97.0934
78 N(75)–S(66)–O(67) 109.4419 199 O(49)–V(21)–O(27) 90.0001
79 N(75)–S(66)–C(64) 109.52 200 O(49)–V(21)–N(10) 19.5346
80 O(68)–S(66)–O(67) 109.4999 116.6 201 O(49)–V(21)–O(8) 90.0001
81 O(68)–S(66)–C(64) 109.4619 202 N(39)–V(21)–O(27) 76.1516
82 O(67)–S(66)–C(64) 109.4619 203 N(39)–V(21)–N(10) 100.2237
83 H(126)–C(65)–C(64) 120.0002 120 204 N(39)–V(21)–O(8) 34.1154
84 H(126)–C(65)–C(60) 119.9995 120 205 O(27)–V(21)–N(10) 109.5001
85 C(64)–C(65)–C(60) 120.0003 206 O(27)–V(21)–O(8) 109.5002
86 S(66)–C(64)–C(65) 120.0001 207 N(10)–V(21)–O(8) 82.5412
87 S(66)–C(64)–C(63) 120.0002 208 H(91)–C(13)–H(90) 109.52 109.4
88 C(65)–C(64)–C(63) 119.9997 120 209 H(91)–C(13)–C(12) 109.4615 109.41
89 H(125)–C(63)–C(64) 119.9998 120 210 H(91)–C(13)–C(9) 109.4618 109.41
90 H(125)–C(63)–C(62) 120.0002 120 211 H(90)–C(13)–C(12) 109.4417 109.41
91 C(64)–C(63)–C(62) 119.9999 212 H(90)–C(13)–C(9) 109.4421 109.41
92 H(124)–C(62)–C(63) 119.9995 120 213 C(12)–C(13)–C(9) 109.5002 109.5
93 H(124)–C(62)–C(61) 120.0004 120 214 C(41)–N(10)–V(21) 118.6942
94 C(63)–C(62)–C(61) 120.0001 215 C(41)–N(10)–C(9) 118.6943 124
95 H(123)–C(60)–C(65) 120.0003 120 216 V(21)–N(10)–C(9) 122.6116
96 H(123)–C(60)–C(61) 120.0002 120 217 C(19)–C(14)–C(15) 119.9997 120
97 C(65)–C(60)–C(61) 119.9995 218 C(19)–C(14)–N(3) 120 120
98 N(59)–S(46)–O(48) 109.4422 219 C(15)–C(14)–N(3) 120.0003 120
99 N(59)–S(46)–O(47) 109.4417 220 C(13)–C(9)–N(10) 119.9999 125.3
100 N(59)–S(46)–C(44) 109.5202 221 C(13)–C(9)–C(6) 120 121.4
101 O(48)–S(46)–O(47) 109.4998 116.6 222 N(10)–C(9)–C(6) 120.0001 120
102 O(48)–S(46)–C(44) 109.4617 223 V(21)–O(8)–C(7) 109.4998
103 O(47)–S(46)–C(44) 109.4617 224 O(8)–C(7)–C(6) 124.2983 124.3
104 H(118)–C(45)–C(44) 120.0003 120 225 O(8)–C(7)–N(3) 124.6983
105 H(118)–C(45)–C(40) 120 120 226 C(6)–C(7)–N(3) 111 120
106 C(44)–C(45)–C(40) 119.9998 227 H(99)–C(20)–H(98) 109.5198 109
107 S(46)–C(44)–C(45) 119.9998 228 H(99)–C(20)–H(97) 109.4618 109
108 S(46)–C(44)–C(43) 119.9995 229 H(99)–C(20)–C(5) 109.4619 110
109 C(45)–C(44)–C(43) 120.0007 120 230 H(98)–C(20)–H(97) 109.4418 109
110 H(117)–C(43)–C(44) 120.0005 120 231 H(98)–C(20)–C(5) 109.4419 110
111 H(117)–C(43)–C(42) 120.0002 120 232 H(97)–C(20)–C(5) 109.5001 110
112 C(44)–C(43)–C(42) 119.9993 233 C(9)–C(6)–C(7) 119.9986 120
113 H(116)–C(42)–C(43) 119.9997 120 234 C(9)–C(6)–C(5) 128.998 120
114 H(116)–C(42)–C(41) 120 120 235 C(7)–C(6)–C(5) 111 120
115 C(43)–C(42)–C(41) 120.0003 236 C(14)–N(3)–C(7) 128.3535 124
116 H(115)–C(40)–C(45) 120.0002 120 237 C(14)–N(3)–N(4) 128.3536 124
117 H(115)–C(40)–C(41) 119.9998 120 237 C(7)–N(3)–N(4) 103.2929 124
118 C(45)–C(40)–C(41) 120 239 C(20)–C(5)–C(6) 124.5 121.4
119 H(110)–C(36)–C(37) 120.0002 120 240 C(20)–C(5)–N(4) 124.5001 115.1
120 H(110)–C(36)–C(35) 120.0001 120 241 C(6)–C(5)–N(4) 110.9999 120
121 C(37)–C(36)–C(35) 119.9997 242 C(5)–N(4)–N(3) 103.7073 115

4

4 Conclusions

The satisfactory analytical data coupled with the studies presented above suggest that the complexes prepared in this investigation are of the general composition[VO(L)2(H2O)]·H2O, where LH = bumphp-sdzH (1), bumphp-sgnH (2), bumphp-snmH (3) or bumphp-smrH (4). Keeping view of the monomeric hexacoordination of all the complexes, and the well established square pyramidal structure (Sakurai et al., 1995) of bis(picolinato)oxovanadium(IV)[involving a monobasic bidentate (O,N)-donor picolinate ligand similar to monobasic (O,N)-donor sulfa drug Schiff base ligands LH in the present investigation, and occupying equatorial positions cis to each other, and oxo group at one of the axial positions], octahedral structures (Fig. 9) with an axial oxo group and a water molecule trans to O (oxo), and two O,N-donor LH ligands at the equatorial positions cis to each other, have been proposed for these complexes. We have already proposed a similar octahedral structure (Maurya et al., 2002a,b,c) for hexa-coordinated oxovanadium(IV) complexes of the compositions,[VO(L1)2(H2O)] where, L1H (O,N-donor) = N-(4′-benzoylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)-p-anisidine, N-(4′-benzoylid-ene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)-m-phenetidine or N-(4′-benzoylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)-p-toluidine, and[VO(L2) (H2O)], where L2H(O2N2) = N-(4′-benzoylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)-o-phenylenediamine or N-(4′-benzoylidene-3′-methyl-1′-phenyl-2′-pyrazolin-5′-one)-m-phenylenediamine.

Proposed octahedral structure of oxovanadium(IV) complexes.
Figure 9
Proposed octahedral structure of oxovanadium(IV) complexes.

Acknowledgments

Authors are thankful to the Prof. R. R. Mishra, Vice-Chancellor R. D. University, Jabalpur, for the encouragement. Analytical facilities provided by the Central Drug Research Institute, Lucknow, India, and the Regional Sophisticated Instrumentation Centre, Indian Institute of Technology, Chennai and Mumbai, India are gratefully acknowledged.

References

  1. , , , , . Eur. J. Med. Chem.. 2004;39:593.
  2. , , , . Acta Crystallogr. Sect. C. 1983;39:1620.
  3. , , , , . J. Biol. Inorg. Chem.. 2003;8:459.
  4. , , , , . Breast Cancer Res. Treat.. 2000;63:133.
  5. , , , , . Cancer Lett.. 2010;294:1.
  6. , , eds. , , , eds. Comprehensive Coordination Chemistry Vol vol. 3. (first ed.). Oxford: Pergamon Press; . p. :540.
  7. , , . Metal Ions in Biological Systems. Vol vol. 116. New York: Marcel Dekker; . p. 261
  8. , , , , , , . J. Inorg. Biochem.. 1983;51:689. and references cited therein
  9. , , , , , . Life Sci.. 2006;78:2839.
  10. , , , , , , , . Cancer Cell. Int.. 2005;5:16.
  11. , , , . Bioorg. Med. Chem.. 2005;13:2459.
  12. CS Chem 3D Ultra Molecular Modeling and Analysis, Cambridge. <www.cambridgesoft.com>.
  13. , , , . Polyhedron. 1996;15:1806.
  14. , , . Expert Opin. Investig. Drugs. 2002;11:1829.
  15. , , , . Biochem. Biophys. Res. Commun.. 2003;302:253.
  16. , , , , , . Inorg. Chim. Acta. 2008;361:132.
  17. , . Anticancer Res.. 2004;24:1529.
  18. , , , , , , , , . Carcinogenesis. J. Chem.. 1999;20:663.
  19. , , , , , , . IL Farmaco. 2005;60:307.
  20. , , eds. Electron spin resonance, , eds. Elements of Magneto Chemistry (second ed.). New Delhi: Affiliated East-West Press Pvt. Ltd.; . p. :225.
  21. , , , . Polyhedron. 1997;16:1863.
  22. , , , , , . Br. J. Cancer. 2005;92:690.
  23. , , , , . J. Inorg. Biochem.. 2002;88:94.
  24. , , , , , , . J. Biol. Inorg. Chem.. 2008;13:435.
  25. , . Crit. Rev. Oncol. Hematol.. 2002;42:249.
  26. , , . Mutat. Res.. 2001;475:1.
  27. , , , , , , , , , , , , , , , , , , . Cancer Res.. 2002;62:6116.
  28. , . Standard Methods of Chemical Analysis Vol vol. I. (sixth ed.). New Jersey: Van D. Nostrand Company, Inc.; . p.1211
  29. , , , . Bioorg. Med. Chem.. 2004;12:651.
  30. , , . J. Med. Chem.. 1970;13:1250.
  31. , . Coord. Chem. Rev.. 1971;7:81.
  32. , , , , , . Inorg. Chim. Acta. 2005;358:989.
  33. , , . The Pharmacological Basis of Therapeutics (fourth ed.). London: McMillan and Co.; .
  34. , . Acta Chem. Scand.. 1959;13:1670.
  35. , . Acta Chem. Scand.. 1959;13:1347. 1668, 1890
  36. , , , , , , . J. Biochem. Mol. Toxicol.. 2003;17:357.
  37. , , , , , , , . Environ. Mol. Mutagen.. 2004;44:113.
  38. , , , , . Cell Biol. Toxicol.. 2005;21:41.
  39. , , , . Acta Chem. Scand.. 1965;343:154.
  40. , , . Laboratory Techniques in Electroanalytical Chemistry. New York: Marcel Dekker; . p. 90
  41. , . Inorganic Electronic Spectroscopy (second ed.). New York: Elsevier; . p. 387
  42. , , , , , . Inorg. Biochem.. 2005;99:589. and references cited therein
  43. , , , , , , . Inorg. Chim. Acta. 2000;307:97.
  44. , , , , , , . Inorg. Chim. Acta. 2000;299:65. and references cited therein
  45. , , , . Coord. Chem. Rev.. 2005;249:2909.
  46. , , . J. Mol. Struct.. 2004;687:35.
  47. , , . J. Mol. Struct.. 2006;794:24.
  48. , , . J. Mol. Struct.. 2007;833:133.
  49. , , , , . Synth. React. Inorg. Met.-Org. Chem.. 1994;26:1013.
  50. , , , , . Synth. React. Inorg. Met.-Org. Chem.. 1996;28:1265.
  51. , , , . Indian J. Chem.. 1997;36A:406.
  52. , , , , . Indian J. Chem.. 2001;40A:1053.
  53. , , , . Synth. React. Inorg. Met.-Org. Chem.. 2002;32:231.
  54. , , , . Synth. React. Inorg. Met.-Org. Chem.. 2002;32:231.
  55. , , , . Synth. React. Inorg.-Met. Org. Chem.. 2002;32:231.
  56. , , , . Synth. React. Inorg.-Met. Org. Chem.. 2003;33:810.
  57. , , , . Indian J. Chem.. 2004;43A:763.
  58. , , , . Indian J. Chem.. 2007;46A:1594.
  59. , , , . Indian J. Chem.. 2008;47A:517.
  60. Maurya, R. C., Martin, M. H., Chourasia, J., Sharma A. K., in press, Intern. J. Curr. Chem.
  61. , , , , , , . Bioorg. Med. Chem. Lett.. 1999;9:1843. and references cited therein
  62. , , . Spectrochim. Acta, Part A. 2007;68:1382.
  63. , , , , . Cancer Chemother. Pharmacol.. 2004;53:163.
  64. , , , . Cancer Chemother. Pharmacol.. 2008;61:67. and references cited therein
  65. , , , , . Eur. J. Med. Chem.. 2005;40:361.
  66. , , , . Inorg. Chim. Acta. 2003;356(2003):121.
  67. , , , , , , . Inorg. Chem.. 2006;45:8086. and references cited therein
  68. , , , , , . Biochim. Biophys. Acta. 2004;1675:165.
  69. , , , , , . Cell Biochem. Funct.. 2004;23:447.
  70. , , , , , . Nutr. Cancer. 2005;51:184.
  71. , , , , . Int. J. Cancer. 2006;120:13.
  72. , , , , . Dalton Trans. 2007:4884.
  73. , , , , . Biochem. Biophys. Res. Commun.. 1995;214:1095.
  74. , , , , , . Coord. Chem. Rev.. 2002;226:187.
  75. , . Coord. Chem. Rev.. 1966;1:293.
  76. , , , , , , , , . Clin. Cancer Res.. 2004;10:1430.
  77. , , , , , , . Antiviral Res.. 2003;58:265.
  78. , , . Eur. J. Med. Chem.. 2005;40:377.
  79. , ed. Encyclopedia of Chemicals, Drugs and Biologicals (10th Ed.). Rahway, N.J., USA: Merck and Co. Inc.; .
  80. , , . Coord. Chem. Rev.. 2001;219-221:1033.
  81. , , . J. Inorg. Biochem.. 2006;100:1925.
  82. , , , . Coord. Chem. Rev.. 1999;99:2561.
  83. , , , , , , , , , , , , . J. Med. Chem.. 1997;40:1018.
  84. , , . Cancer Chemother.. 1962;21:137.
  85. , , , , , , , , , . Bioorg. Med. Chem. Lett.. 2005;15:2275.
  86. , , , , , , , , , . J. Med. Chem.. 1992;35:2496.
  87. , , , , , . Inorg. Chim. Acta. 2008;361:359.
Show Sections